The Department of Physiology and Pharmacology, Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, NC 27157-1083, USA.
Trends Endocrinol Metab. 1996 May-Jun;7(4):145-50. doi: 10.1016/1043-2760(96)00043-4.
It is widely accepted that during the aging process a number of alterations occur at the molecular, cellular, and tissue levels, ranging from an alteration in receptor signal transduction and gene expression to structural and morphological changes in various tissues. There is abundant empirical and scientific evidence to support the hypothesis that many of these aging processes are closely related to a decline in hormone concentrations and/or hormone action, but the etiology of these deficiencies remains elusive. GH and insulinlike growth factor-I (IGF-I) are two potent anabolic hormones that decrease with age and appear to contribute to the loss of tissue function that is associated with normal aging. In this review, age-related changes in the regulation of these hormones are detailed as well as relatively new information on mechanisms of tissue resistance to GH. Finally, the potential use of GH as a therapeutic intervention to delay physiological changes associated with age is discussed.
人们普遍认为，在衰老过程中，分子、细胞和组织水平会发生多种变化，从受体信号转导和基因表达的改变到各种组织的结构和形态变化。有大量的经验和科学证据支持这样一种假设，即许多这些衰老过程与激素浓度和/或激素作用的下降密切相关，但这些缺陷的病因仍然难以捉摸。生长激素（GH）和胰岛素样生长因子-I（IGF-I）是两种强效的合成代谢激素，它们随年龄增长而减少，似乎与正常衰老相关的组织功能丧失有关。在这篇综述中，详细描述了这些激素的调节与年龄相关的变化，以及关于组织对 GH 抵抗的机制的相对较新的信息。最后，讨论了使用 GH 作为治疗干预以延缓与年龄相关的生理变化的潜力。
